Duopharma Biotech Bhd
Duopharma Biotech Berhad, an investment holding company, researches, develops, manufactures, distributes, and imports pharmaceutical products and medicines in Malaysia and internationally. The company offers consumer healthcare products, such as vitamins, minerals, and supplements, analgesics, eyecare, antacids, and skin care products; and generic drugs for various therapeutic classes, such as ca… Read more
Market Cap & Net Worth: Duopharma Biotech Bhd (7148)
Duopharma Biotech Bhd (KLSE:7148) has a market capitalization of $286.19 Million (RM1.29 Billion) as of March 18, 2026. Listed on the KLSE stock exchange, this Malaysia-based company holds position #16978 globally and #132 in its home market, demonstrating a -10.67% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Duopharma Biotech Bhd's stock price RM1.34 by its total outstanding shares 961942451 (961.94 Million).
Duopharma Biotech Bhd Market Cap History: 2015 to 2026
Duopharma Biotech Bhd's market capitalization history from 2015 to 2026. Data shows growth from $140.62 Million to $286.19 Million (6.79% CAGR).
Duopharma Biotech Bhd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Duopharma Biotech Bhd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.29x
Duopharma Biotech Bhd's market cap is 0.29 times its annual revenue
1.01x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
3.05x
Duopharma Biotech Bhd's market cap is 3.05 times its annual earnings
10.29x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $110.25 Million | $312.94 Million | $26.83 Million | 0.35x | 4.11x |
| 2017 | $145.04 Million | $467.99 Million | $42.46 Million | 0.31x | 3.42x |
| 2018 | $131.20 Million | $498.72 Million | $47.64 Million | 0.26x | 2.75x |
| 2019 | $203.41 Million | $576.46 Million | $55.27 Million | 0.35x | 3.68x |
| 2020 | $500.00 Million | $569.90 Million | $58.61 Million | 0.88x | 8.53x |
| 2021 | $339.63 Million | $639.17 Million | $65.68 Million | 0.53x | 5.17x |
| 2022 | $330.51 Million | $696.72 Million | $70.11 Million | 0.47x | 4.71x |
| 2023 | $262.87 Million | $704.73 Million | $52.65 Million | 0.37x | 4.99x |
| 2024 | $266.97 Million | $813.70 Million | $62.65 Million | 0.33x | 4.26x |
| 2025 | $266.97 Million | $931.69 Million | $87.46 Million | 0.29x | 3.05x |
Competitor Companies of 7148 by Market Capitalization
Companies near Duopharma Biotech Bhd in the global market cap rankings as of March 18, 2026.
Key companies related to Duopharma Biotech Bhd by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #423 globally with a market cap of $51.97 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #455 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #719 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #423 | Zoetis Inc | NYSE:ZTS | $51.97 Billion | $118.15 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.46 |
| #455 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #719 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Duopharma Biotech Bhd Historical Marketcap From 2015 to 2026
Between 2015 and today, Duopharma Biotech Bhd's market cap moved from $140.62 Million to $ 286.19 Million, with a yearly change of 6.79%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | RM286.19 Million | +7.20% |
| 2025 | RM266.97 Million | 0.00% |
| 2024 | RM266.97 Million | +1.56% |
| 2023 | RM262.87 Million | -20.47% |
| 2022 | RM330.51 Million | -2.69% |
| 2021 | RM339.63 Million | -32.07% |
| 2020 | RM500.00 Million | +145.81% |
| 2019 | RM203.41 Million | +55.04% |
| 2018 | RM131.20 Million | -9.54% |
| 2017 | RM145.04 Million | +31.56% |
| 2016 | RM110.25 Million | -21.60% |
| 2015 | RM140.62 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Duopharma Biotech Bhd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $286.19 Million USD |
| MoneyControl | $286.19 Million USD |
| MarketWatch | $286.19 Million USD |
| marketcap.company | $286.19 Million USD |
| Reuters | $286.19 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.